Market Place
Sourcing Support
IMUNON Reports Q3 2024 Financial Results & Business Updates
07 Nov 2024 //
GLOBENEWSWIRE
IMUNON Presents OVATION 2 Data on IMNN-001 in Ovarian Cancer
07 Nov 2024 //
GLOBENEWSWIRE
Imunon to Hold Q3 2024 Results Conference Call on Nov 7
31 Oct 2024 //
GLOBENEWSWIRE
Imunon to Present Phase 2 Data at SITC Annual Meeting
30 Oct 2024 //
GLOBENEWSWIRE
Imunon Reports Inducement Grant Under NASDAQ LR 5635(c)(4)
07 Oct 2024 //
GLOBENEWSWIRE
Imunon`s Ovarian Cancer R&D Day To Feature Presentations
09 Sep 2024 //
GLOBENEWSWIRE
IMUNON to Host R&D Day on September 18th
28 Aug 2024 //
GLOBENEWSWIRE
IMUNON Reports Q2 2024 Financial Results And Business Update
14 Aug 2024 //
GLOBENEWSWIRE
IMUNON To Hold Q2 2024 Financial Results Call On August 14
07 Aug 2024 //
GLOBENEWSWIRE
IMUNON Announces $10M Registered Direct Offering
31 Jul 2024 //
GLOBENEWSWIRE
IMUNON Reports 11.1 Month OS Increase In Ovarian Cancer Study
30 Jul 2024 //
GLOBENEWSWIRE
IMUNON To Report OVATION 2 Study Results For IMNN-001 In Ovarian Cancer
29 Jul 2024 //
GLOBENEWSWIRE
IMUNON Announces Database Lock for Phase 2 OVATION 2 Study in Ovarian Cancer
24 Jun 2024 //
GLOBENEWSWIRE
First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial
05 Jun 2024 //
GLOBENEWSWIRE
IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update
13 May 2024 //
GLOBENEWSWIRE
IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study
13 May 2024 //
GLOBENEWSWIRE
IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO
08 May 2024 //
GLOBENEWSWIRE
IMUNON To Host Q1 2024 Results, Business Update Call On May 13
06 May 2024 //
GLOBENEWSWIRE
IMUNON`s IND Application Cleared to Begin Human Testing of IMNN-101
18 Apr 2024 //
GLOBENEWSWIRE
IMUNON Reports 2023 Financial Results and Provides Business Update
28 Mar 2024 //
GLOBENEWSWIRE
IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses
25 Mar 2024 //
GLOBENEWSWIRE
IMUNON to Hold 2023 Financial Results and Business Update
21 Mar 2024 //
GLOBENEWSWIRE
IMUNON Files IND Application to Begin Human Testing of IMNN-101
13 Mar 2024 //
GLOBENEWSWIRE
IMUNON Announces Leadership Change
12 Mar 2024 //
GLOBENEWSWIRE
Independent Lab Confirms Immunogenicity and Protection with IMUNON™s IMNN-101
29 Feb 2024 //
GLOBENEWSWIRE
Memorial Sloan Kettering Cancer Center Enrolling in Phase 1/2 Trial of IMNN-001
27 Feb 2024 //
GLOBENEWSWIRE
IMNN-101 Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine
22 Feb 2024 //
GLOBENEWSWIRE
IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer
11 Dec 2023 //
GLOBENEWSWIRE
IMUNON Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
GLOBENEWSWIRE
IMUNON™s VP of R&D to Present at the Vaccines Summit-2023
14 Nov 2023 //
GLOBENEWSWIRE
IMUNON to Hold Third Quarter 2023 Financial Results Conference
07 Nov 2023 //
GLOBENEWSWIRE
IMUNON™s CSO to Present at the 3rd International Vaccines Congress
23 Oct 2023 //
GLOBENEWSWIRE
IMUNON CEO Dr. Corinne Le Goff to Participate in a Panel Discussion
19 Oct 2023 //
GLOBENEWSWIRE
IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001
18 Oct 2023 //
GLOBENEWSWIRE
IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board
06 Oct 2023 //
GLOBENEWSWIRE
IMUNON Reports Overall Survival Data in Phase 1/2 OVATION 2 Study
28 Sep 2023 //
GLOBENEWSWIRE
IMUNON Releases Enterprise Video Highlighting the Company™s Mission
26 Sep 2023 //
GLOBENEWSWIRE
IMUNON to Host Virtual R&D Day on September 14th Beginning at 4:00 p.m. ET
07 Sep 2023 //
GLOBENEWSWIRE
IMUNON to Participate in the H.C. Wainwright Global Investment Conference
05 Sep 2023 //
GLOBENEWSWIRE
IMUNON Enters into CRADA for Preclinical Studies of PlaCCine Modality
24 Aug 2023 //
GLOBENEWSWIRE
IMUNON Expands Scientific Advisory Board with the Addition of Dr. Sachet Shukla
14 Aug 2023 //
GLOBENEWSWIRE
IMUNON Reports Second Quarter 2023 Financial Results & Provides Business Update
10 Aug 2023 //
GLOBENEWSWIRE
IMUNON to Hold Second Quarter 2023 Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
IMUNON Unveils New Manufacturing Capabilities at Huntsville
27 Jun 2023 //
GLOBENEWSWIRE
Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
26 Jun 2023 //
GLOBENEWSWIRE
IMUNON CEO to Discuss Company Novel Non-viral DNA Therapy Option
12 Jun 2023 //
GLOBENEWSWIRE
IMUNON™s CEO Presents Business Overview to Investors
08 Jun 2023 //
GLOBENEWSWIRE
IMUNON Presents PlaCCine Preclinical Data at the 2023 Viruses and Cells
30 May 2023 //
GLOBENEWSWIRE
IMUNON Reports First Quarter 2023 Financial Results and Provides Business Update
11 May 2023 //
GLOBENEWSWIRE
IMUNON to Hold 1Q 2023 FYR & Business Update Conference Call
04 May 2023 //
GLOBENEWSWIRE
IMUNON Presents Poster at the American Association for Cancer Research
19 Apr 2023 //
GLOBENEWSWIRE
IMUNON Reports 2022 Financial Results and Provides Business Update
30 Mar 2023 //
GLOBENEWSWIRE
IMUNON to Hold Fourth Quarter 2022 Financial Results
23 Mar 2023 //
GLOBENEWSWIRE
IMUNON Presents PLACCINE Data at Vaccine Technology Summit 2023
22 Mar 2023 //
GLOBENEWSWIRE
Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
21 Mar 2023 //
GLOBENEWSWIRE
IMUNON Announces Abstract Accepted for Presentation at American Association
15 Mar 2023 //
GLOBENEWSWIRE
IMUNON CEO Issues Letter to Shareholders
01 Mar 2023 //
GLOBENEWSWIRE
IMUNON and Break Through Cancer Commence Enrollment in P1/2 of IMNN-001
27 Feb 2023 //
GLOBENEWSWIRE
IMUNON Receives $1.6 Million from Sale of its New Jersey Net Operating Losses
12 Jan 2023 //
GLOBENEWSWIRE
